Global Non Small-Cell Lung Cancer Market By Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma, Others), By Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy), By Distribution Channel (Hospital Pharmacy, Drug Store and Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global non-small cell lung cancer treatment market was valued at $15,335.0 million in 2021, and is projected to reach $36,934.19 million by 2031, registering a CAGR of 9.3% from 2022 to 2031.
Non-small cell lung cancer (NSCLC), is a type of lungs cancer that occurs in the epithelial tissues of the lungs. NSCLC mostly occurs in people who smoke or have a history of smoking. It also occurs in people who are exposed to polluted air, such as radon, asbestos, and others. The treatment of cancer in patients requires the use of different techniques, such as immunotherapy, targeted therapy, and chemotherapy.
NSCLC can be cured, especially if action is taken before the disease spreads to other organs. Doctor may only need to do surgery if the cancer is contained to a tiny area of the lungs. Additional therapies may be necessary for a more advanced malignancy. Furthermore, rise in tobacco consumption, rising prevalence of non-small lung cancer market, early screening of the cancer, and availability of cancer drugs are expected to boost the market growth. For instance, according to National Centre for Biotechnology Information (NCBI), 85% of lung cancer diseases are non-small cell lung cancer cases.
However, high cost involved in treatment therapies coupled with threat of adverse side-effects associated with cancer drugs therapies is expected to restrain the growth of the market. Conversely, high potential of emerging economies and higher number of potential drugs in pipeline are expected to provide new opportunities for market players in future.
The global NSCLC treatment market is segmented by type, treatment type, distribution channel, and region. Depending on treatment type, the market is divided into chemotherapy, targeted therapy, and immunotherapy. By type, it is categorized into adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and others (adenosquamous carcinoma, sarcomatoid carcinoma) and by distribution channel, it is segmented into hospital pharmacy, drug stores and retail pharmacy, and online pharmacy.
Region-wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). The major companies profiled in the report include, AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly, F. Hoffmann-La Roche Ltd., Johnson & Johnson (Janssen Global Services, LLC), Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi SA, and Teva Pharmaceuticals Industries Ltd.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global non small cell lung cancer market analysis from 2021 to 2031 to identify the prevailing global non small cell lung cancer market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the global non small cell lung cancer market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global non small cell lung cancer market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
Squamous Cell Carcinoma
Large Cell Carcinoma
Others
Adenocarcinoma
By Treatment Type
Chemotherapy
Targeted Therapy
Immunotherapy
By Distribution Channel
Hospital Pharmacy
Drug Store and Retail Pharmacy
Online Pharmacy
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
F. Hoffmann-La Roche Ltd
Novartis AG
Pfizer Inc.
Astrazeneca
Eli Lilly and Company
Merck & Co., Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Sanofi
boehringer ingelheim
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Adenocarcinoma
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market share analysis by country
- 4.3 Squamous Cell Carcinoma
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market share analysis by country
- 4.4 Large Cell Carcinoma
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market share analysis by country
- 4.5 Others
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market share analysis by country
- CHAPTER 5: GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Chemotherapy
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market share analysis by country
- 5.3 Targeted Therapy
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market share analysis by country
- 5.4 Immunotherapy
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market share analysis by country
- CHAPTER 6: GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Hospital Pharmacy
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market share analysis by country
- 6.3 Drug Store and Retail Pharmacy
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market share analysis by country
- 6.4 Online Pharmacy
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market share analysis by country
- CHAPTER 7: GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Type
- 7.2.3 North America Market size and forecast, by Treatment Type
- 7.2.4 North America Market size and forecast, by Distribution Channel
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Key market trends, growth factors and opportunities
- 7.2.5.1.2 Market size and forecast, by Type
- 7.2.5.1.3 Market size and forecast, by Treatment Type
- 7.2.5.1.4 Market size and forecast, by Distribution Channel
- 7.2.5.2 Canada
- 7.2.5.2.1 Key market trends, growth factors and opportunities
- 7.2.5.2.2 Market size and forecast, by Type
- 7.2.5.2.3 Market size and forecast, by Treatment Type
- 7.2.5.2.4 Market size and forecast, by Distribution Channel
- 7.2.5.3 Mexico
- 7.2.5.3.1 Key market trends, growth factors and opportunities
- 7.2.5.3.2 Market size and forecast, by Type
- 7.2.5.3.3 Market size and forecast, by Treatment Type
- 7.2.5.3.4 Market size and forecast, by Distribution Channel
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Type
- 7.3.3 Europe Market size and forecast, by Treatment Type
- 7.3.4 Europe Market size and forecast, by Distribution Channel
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Key market trends, growth factors and opportunities
- 7.3.5.1.2 Market size and forecast, by Type
- 7.3.5.1.3 Market size and forecast, by Treatment Type
- 7.3.5.1.4 Market size and forecast, by Distribution Channel
- 7.3.5.2 France
- 7.3.5.2.1 Key market trends, growth factors and opportunities
- 7.3.5.2.2 Market size and forecast, by Type
- 7.3.5.2.3 Market size and forecast, by Treatment Type
- 7.3.5.2.4 Market size and forecast, by Distribution Channel
- 7.3.5.3 UK
- 7.3.5.3.1 Key market trends, growth factors and opportunities
- 7.3.5.3.2 Market size and forecast, by Type
- 7.3.5.3.3 Market size and forecast, by Treatment Type
- 7.3.5.3.4 Market size and forecast, by Distribution Channel
- 7.3.5.4 Italy
- 7.3.5.4.1 Key market trends, growth factors and opportunities
- 7.3.5.4.2 Market size and forecast, by Type
- 7.3.5.4.3 Market size and forecast, by Treatment Type
- 7.3.5.4.4 Market size and forecast, by Distribution Channel
- 7.3.5.5 Spain
- 7.3.5.5.1 Key market trends, growth factors and opportunities
- 7.3.5.5.2 Market size and forecast, by Type
- 7.3.5.5.3 Market size and forecast, by Treatment Type
- 7.3.5.5.4 Market size and forecast, by Distribution Channel
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Key market trends, growth factors and opportunities
- 7.3.5.6.2 Market size and forecast, by Type
- 7.3.5.6.3 Market size and forecast, by Treatment Type
- 7.3.5.6.4 Market size and forecast, by Distribution Channel
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Type
- 7.4.3 Asia-Pacific Market size and forecast, by Treatment Type
- 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Key market trends, growth factors and opportunities
- 7.4.5.1.2 Market size and forecast, by Type
- 7.4.5.1.3 Market size and forecast, by Treatment Type
- 7.4.5.1.4 Market size and forecast, by Distribution Channel
- 7.4.5.2 China
- 7.4.5.2.1 Key market trends, growth factors and opportunities
- 7.4.5.2.2 Market size and forecast, by Type
- 7.4.5.2.3 Market size and forecast, by Treatment Type
- 7.4.5.2.4 Market size and forecast, by Distribution Channel
- 7.4.5.3 Australia
- 7.4.5.3.1 Key market trends, growth factors and opportunities
- 7.4.5.3.2 Market size and forecast, by Type
- 7.4.5.3.3 Market size and forecast, by Treatment Type
- 7.4.5.3.4 Market size and forecast, by Distribution Channel
- 7.4.5.4 India
- 7.4.5.4.1 Key market trends, growth factors and opportunities
- 7.4.5.4.2 Market size and forecast, by Type
- 7.4.5.4.3 Market size and forecast, by Treatment Type
- 7.4.5.4.4 Market size and forecast, by Distribution Channel
- 7.4.5.5 South Korea
- 7.4.5.5.1 Key market trends, growth factors and opportunities
- 7.4.5.5.2 Market size and forecast, by Type
- 7.4.5.5.3 Market size and forecast, by Treatment Type
- 7.4.5.5.4 Market size and forecast, by Distribution Channel
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Key market trends, growth factors and opportunities
- 7.4.5.6.2 Market size and forecast, by Type
- 7.4.5.6.3 Market size and forecast, by Treatment Type
- 7.4.5.6.4 Market size and forecast, by Distribution Channel
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Type
- 7.5.3 LAMEA Market size and forecast, by Treatment Type
- 7.5.4 LAMEA Market size and forecast, by Distribution Channel
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Key market trends, growth factors and opportunities
- 7.5.5.1.2 Market size and forecast, by Type
- 7.5.5.1.3 Market size and forecast, by Treatment Type
- 7.5.5.1.4 Market size and forecast, by Distribution Channel
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Key market trends, growth factors and opportunities
- 7.5.5.2.2 Market size and forecast, by Type
- 7.5.5.2.3 Market size and forecast, by Treatment Type
- 7.5.5.2.4 Market size and forecast, by Distribution Channel
- 7.5.5.3 South Africa
- 7.5.5.3.1 Key market trends, growth factors and opportunities
- 7.5.5.3.2 Market size and forecast, by Type
- 7.5.5.3.3 Market size and forecast, by Treatment Type
- 7.5.5.3.4 Market size and forecast, by Distribution Channel
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Key market trends, growth factors and opportunities
- 7.5.5.4.2 Market size and forecast, by Type
- 7.5.5.4.3 Market size and forecast, by Treatment Type
- 7.5.5.4.4 Market size and forecast, by Distribution Channel
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 F. Hoffmann-La Roche Ltd
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Novartis AG
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Pfizer Inc.
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Astrazeneca
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Eli Lilly and Company
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Merck & Co., Inc.
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Bristol-Myers Squibb Company
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Celgene Corporation
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Sanofi
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 boehringer ingelheim
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 2. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR ADENOCARCINOMA, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 3. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR ADENOCARCINOMA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 4. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR SQUAMOUS CELL CARCINOMA, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 5. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR SQUAMOUS CELL CARCINOMA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 6. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR LARGE CELL CARCINOMA, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 7. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR LARGE CELL CARCINOMA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 8. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 9. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 10. GLOBAL GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 11. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR CHEMOTHERAPY, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 12. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 13. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR TARGETED THERAPY, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 14. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR TARGETED THERAPY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 15. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR IMMUNOTHERAPY, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 16. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR IMMUNOTHERAPY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 17. GLOBAL GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 18. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 19. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 20. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR DRUG STORE AND RETAIL PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 21. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR DRUG STORE AND RETAIL PHARMACY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 22. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR ONLINE PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 23. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 24. GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 25. NORTH AMERICA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 26. NORTH AMERICA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 27. NORTH AMERICA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 28. NORTH AMERICA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 29. U.S. GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 30. U.S. GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 31. U.S. GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 32. CANADA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 33. CANADA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 34. CANADA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 35. MEXICO GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 36. MEXICO GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 37. MEXICO GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 38. EUROPE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 39. EUROPE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 40. EUROPE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 41. EUROPE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 42. GERMANY GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 43. GERMANY GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 44. GERMANY GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 45. FRANCE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 46. FRANCE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 47. FRANCE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 48. UK GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 49. UK GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 50. UK GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 51. ITALY GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 52. ITALY GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 53. ITALY GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 54. SPAIN GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 55. SPAIN GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 56. SPAIN GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 57. REST OF EUROPE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 58. REST OF EUROPE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 59. REST OF EUROPE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 60. ASIA-PACIFIC GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 61. ASIA-PACIFIC GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 62. ASIA-PACIFIC GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 63. ASIA-PACIFIC GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 64. JAPAN GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 65. JAPAN GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 66. JAPAN GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 67. CHINA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 68. CHINA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 69. CHINA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 70. AUSTRALIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 71. AUSTRALIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 72. AUSTRALIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 73. INDIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 74. INDIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 75. INDIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 76. SOUTH KOREA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 77. SOUTH KOREA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 78. SOUTH KOREA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 79. REST OF ASIA-PACIFIC GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 80. REST OF ASIA-PACIFIC GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 81. REST OF ASIA-PACIFIC GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 82. LAMEA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 83. LAMEA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 84. LAMEA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 85. LAMEA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 86. BRAZIL GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 87. BRAZIL GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 88. BRAZIL GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 89. SAUDI ARABIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 90. SAUDI ARABIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 91. SAUDI ARABIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 92. SOUTH AFRICA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 93. SOUTH AFRICA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 94. SOUTH AFRICA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 95. REST OF LAMEA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 96. REST OF LAMEA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 97. REST OF LAMEA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 98.F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
- TABLE 99.F. HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
- TABLE 100.F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
- TABLE 101.F. HOFFMANN-LA ROCHE LTD: NET SALES
- TABLE 102.F. HOFFMANN-LA ROCHE LTD: KEY STRATERGIES
- TABLE 103.NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 104.NOVARTIS AG: OPERATING SEGMENTS
- TABLE 105.NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 106.NOVARTIS AG: NET SALES
- TABLE 107.NOVARTIS AG: KEY STRATERGIES
- TABLE 108.PFIZER INC.: COMPANY SNAPSHOT
- TABLE 109.PFIZER INC.: OPERATING SEGMENTS
- TABLE 110.PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 111.PFIZER INC.: NET SALES
- TABLE 112.PFIZER INC.: KEY STRATERGIES
- TABLE 113.ASTRAZENECA: COMPANY SNAPSHOT
- TABLE 114.ASTRAZENECA: OPERATING SEGMENTS
- TABLE 115.ASTRAZENECA: PRODUCT PORTFOLIO
- TABLE 116.ASTRAZENECA: NET SALES
- TABLE 117.ASTRAZENECA: KEY STRATERGIES
- TABLE 118.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
- TABLE 119.ELI LILLY AND COMPANY: OPERATING SEGMENTS
- TABLE 120.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
- TABLE 121.ELI LILLY AND COMPANY: NET SALES
- TABLE 122.ELI LILLY AND COMPANY: KEY STRATERGIES
- TABLE 123.MERCK & CO., INC.: COMPANY SNAPSHOT
- TABLE 124.MERCK & CO., INC.: OPERATING SEGMENTS
- TABLE 125.MERCK & CO., INC.: PRODUCT PORTFOLIO
- TABLE 126.MERCK & CO., INC.: NET SALES
- TABLE 127.MERCK & CO., INC.: KEY STRATERGIES
- TABLE 128.BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
- TABLE 129.BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
- TABLE 130.BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
- TABLE 131.BRISTOL-MYERS SQUIBB COMPANY: NET SALES
- TABLE 132.BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
- TABLE 133.CELGENE CORPORATION: COMPANY SNAPSHOT
- TABLE 134.CELGENE CORPORATION: OPERATING SEGMENTS
- TABLE 135.CELGENE CORPORATION: PRODUCT PORTFOLIO
- TABLE 136.CELGENE CORPORATION: NET SALES
- TABLE 137.CELGENE CORPORATION: KEY STRATERGIES
- TABLE 138.SANOFI: COMPANY SNAPSHOT
- TABLE 139.SANOFI: OPERATING SEGMENTS
- TABLE 140.SANOFI: PRODUCT PORTFOLIO
- TABLE 141.SANOFI: NET SALES
- TABLE 142.SANOFI: KEY STRATERGIES
- TABLE 143.BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
- TABLE 144.BOEHRINGER INGELHEIM: OPERATING SEGMENTS
- TABLE 145.BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
- TABLE 146.BOEHRINGER INGELHEIM: NET SALES
- TABLE 147.BOEHRINGER INGELHEIM: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.GLOBAL NON SMALL-CELL LUNG CANCER MARKET SEGMENTATION
- FIGURE 2.GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031
- FIGURE 3.GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.GLOBAL NON SMALL-CELL LUNG CANCER MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.GLOBAL NON SMALL-CELL LUNG CANCER MARKET,BY TYPE,2021(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ADENOCARCINOMA GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF SQUAMOUS CELL CARCINOMA GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF LARGE CELL CARCINOMA GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OTHERS GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031(%)
- FIGURE 17.GLOBAL NON SMALL-CELL LUNG CANCER MARKET,BY TREATMENT TYPE,2021(%)
- FIGURE 18.COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF TARGETED THERAPY GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF IMMUNOTHERAPY GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031(%)
- FIGURE 21.GLOBAL NON SMALL-CELL LUNG CANCER MARKET,BY DISTRIBUTION CHANNEL,2021(%)
- FIGURE 22.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACY GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF DRUG STORE AND RETAIL PHARMACY GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031(%)
- FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACY GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031(%)
- FIGURE 25.GLOBAL NON SMALL-CELL LUNG CANCER MARKET BY REGION,2021
- FIGURE 26.U.S. GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
- FIGURE 27.CANADA GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
- FIGURE 28.MEXICO GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
- FIGURE 29.GERMANY GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
- FIGURE 30.FRANCE GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
- FIGURE 31.UK GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
- FIGURE 32.ITALY GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
- FIGURE 33.SPAIN GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
- FIGURE 34.REST OF EUROPE GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
- FIGURE 35.JAPAN GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
- FIGURE 36.CHINA GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
- FIGURE 37.AUSTRALIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
- FIGURE 38.INDIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
- FIGURE 39.SOUTH KOREA GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
- FIGURE 40.REST OF ASIA-PACIFIC GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
- FIGURE 41.BRAZIL GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
- FIGURE 42.SAUDI ARABIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
- FIGURE 43.SOUTH AFRICA GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
- FIGURE 44.REST OF LAMEA GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
- FIGURE 45. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 48.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 49.COMPETITIVE DASHBOARD
- FIGURE 50.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 51.F. HOFFMANN-LA ROCHE LTD.: NET SALES ($MILLION)
- FIGURE 52.NOVARTIS AG.: NET SALES ($MILLION)
- FIGURE 53.PFIZER INC..: NET SALES ($MILLION)
- FIGURE 54.ASTRAZENECA.: NET SALES ($MILLION)
- FIGURE 55.ELI LILLY AND COMPANY.: NET SALES ($MILLION)
- FIGURE 56.MERCK & CO., INC..: NET SALES ($MILLION)
- FIGURE 57.BRISTOL-MYERS SQUIBB COMPANY.: NET SALES ($MILLION)
- FIGURE 58.CELGENE CORPORATION.: NET SALES ($MILLION)
- FIGURE 59.SANOFI.: NET SALES ($MILLION)
- FIGURE 60.BOEHRINGER INGELHEIM.: NET SALES ($MILLION)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook